

图 1



	PDL1-27	PDL1-56
EC50	5.680	5.304

图 2



	PDL1-27	PDL1-56
EC50	917.3	143.9

图 3



图 4



图 5



图 6



图 7



图 8


50
40
30
20
10
0
MFI
0.0
0.5
1.0
1.5
2.0
2.5
Log[Concentration] (ug/ml)
EC50
13.42

图 9



图 10

		MFI
A02	293 APC only	8
A05	293 vector-KN035	353
A03	293 hPD-L1-KN035	2874
A04	293 cmPD-L1-KN035	2821



图 11





图 12


800
600
400
200
0
IFN-γ (pg/ml)
antiCD3 - + + + + (2.5 ug/ml)
KN035 - 0 0.001 0.1 10 (ug/ml)

图 13


MLR assay
IFN-γ (ng/ml)
0
20
40
60
80
0
0.1
KN035 (μg/ml)

图 14 A


IFN-γ expression(ng/ml)
0
5
10
15
20
2.41
hu56V1-Fcm1
20
2
0.2
0.02
0.002
0.0002
0
Concentration(ug/ml)

图 14 B


140
120
100
80
60
IL-2 Expression(pg/ml)
hu56V1-Fcm1
2.41
5
1
0.2
0.04
0.008
0
Concentration(nM)

图 15


ADCC(%)
Rituxan
hu56V1-Fcm1
ADCC Cytotoxicity(%)
30
20
10
0
-10
10000
1000
100
10
1
Concentration(ng/ml)

图 16 A


CDC Activity(%)
Rituxan
hu56V1-Fcm1
Cytotoxicity(%)
100
90
80
70
60
50
40
30
20
10
0
-10
20
2
0.2
0.02
Concentration(ug/ml)

图 16 B


Tumor volume (mm3)
400
300
200
100
0
7
10
14
17
21
days
control
KN035

图 17 A


Tumor Volume (Mean±SEM,mm^3)
2500
2000
1500
1000
500
0
9
12
15
18
21
24
27
30
33
36
Days After Treatment
PBS
0.1mg/kg
0.3mg/kg
1mg/kg
3mg/kg
10mg/kg

图 17 B


PBS/ip/1, 4 , 7, 10
0.3mg/kg/ip/1
0.3mg/kg/ip/1, 4
0.3mg/kg/ip/1, 4, 7
0.3mg/kg/ip/1, 4 , 7, 10
Tumor Volume(mm^3)
2000
1800
1600
1400
1200
1000
800
600
400
200
0
3
6
9
12
15
18
21
24
27
30
33
Days After Treatment

图 18


A375 (NOD-SCID)
2500
2000
1500
1000
500
0
Volume(mm 3)
7d
11d
14d
18d
21d
25d
28d
32d
35d
39d
42d
Time
PBS
HJ56
2.41

图 19A


8000
6000
4000
2000
0
Volume(mm3)
7d
11d
14d
18d
21d
25d
28d
32d
35d
39d
42d
Time
PBS
2.41H90P

图 19B



	KN035 强碱 0h	KN035 强碱14h	KN035 强碱22h	KN035 强碱38h	KN035 氧化 4h	KN035 氧化 8h
EC50	341.6	330.4	350.8	330.1	303.9	321.6

图 20